Recently, scRNA-seq technology was used to predict the therapeutic efficacy or uncover transcriptional changes during the treatment of T1D in some clinical trials, including in children with new-onset T1D [68], in individuals at risk for T1D [69], and in T1D patients with GAD-alum immunotherapy [70]. This evidence concerns the gene GAD1 and type 1 diabetes mellitus.